Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
SUBUTEX is a sublingual tablet containing buprenorphine, a partial opioid agonist used for opioid use disorder maintenance treatment and pain management. The drug works by binding to opioid receptors with high affinity while producing a ceiling effect that reduces overdose risk compared to full agonists. It is a cornerstone medication in medication-assisted treatment (MAT) programs.
Product is entering late-stage lifecycle with moderate competitive pressure (30), suggesting consolidation of commercial teams and shift toward defensive positioning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Transfer of Subjects From Subutex/Suboxone to RBP-6300
Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Worked on SUBUTEX at Indivior? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SUBUTEX offers stability in a mature, essential therapeutic area with consistent patient demand, but limited growth trajectory. Professionals joining this team should expect focus on operational excellence, regulatory maintenance, and defending market position rather than expansion.